{"title":"日本第三版高尿酸血症和痛风治疗指南的制定","authors":"I. Hisatome, A. Ohtahara, T. Hamada, K. Ogino","doi":"10.6032/GNAM.42.147","DOIUrl":null,"url":null,"abstract":"Because of accumulation of information on hyperuricemia and gout since 2010, the 3 rd edition of the guideline for the management of hyperuricemia and gout is now going to be processed. After setting the important clinical issues on hyperuricemia and gout, seven clinical questions accompanied by several advantage and disadvantage outcomes have been selected. Using the systematic reviews on reports related to outcome of each clinical question, bias risk of each evidence has been estimated. Taken together with the estimation of body of evidence, the recommendation for the each clinical question will be determined. In addition to clinical questions, review paper regarding the clinical issues of hyperuricemia and gout will be prepared. Thus, this guideline is expected to cover the decision making regarding the important clinical issues on hyperuricemia and gout.","PeriodicalId":12746,"journal":{"name":"GOUT AND NUCLEIC ACID METABOLISM","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Development of Guideline for the management of hyperuricemia and gout in Japan 3rd edition\",\"authors\":\"I. Hisatome, A. Ohtahara, T. Hamada, K. Ogino\",\"doi\":\"10.6032/GNAM.42.147\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Because of accumulation of information on hyperuricemia and gout since 2010, the 3 rd edition of the guideline for the management of hyperuricemia and gout is now going to be processed. After setting the important clinical issues on hyperuricemia and gout, seven clinical questions accompanied by several advantage and disadvantage outcomes have been selected. Using the systematic reviews on reports related to outcome of each clinical question, bias risk of each evidence has been estimated. Taken together with the estimation of body of evidence, the recommendation for the each clinical question will be determined. In addition to clinical questions, review paper regarding the clinical issues of hyperuricemia and gout will be prepared. Thus, this guideline is expected to cover the decision making regarding the important clinical issues on hyperuricemia and gout.\",\"PeriodicalId\":12746,\"journal\":{\"name\":\"GOUT AND NUCLEIC ACID METABOLISM\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GOUT AND NUCLEIC ACID METABOLISM\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6032/GNAM.42.147\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GOUT AND NUCLEIC ACID METABOLISM","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6032/GNAM.42.147","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Development of Guideline for the management of hyperuricemia and gout in Japan 3rd edition
Because of accumulation of information on hyperuricemia and gout since 2010, the 3 rd edition of the guideline for the management of hyperuricemia and gout is now going to be processed. After setting the important clinical issues on hyperuricemia and gout, seven clinical questions accompanied by several advantage and disadvantage outcomes have been selected. Using the systematic reviews on reports related to outcome of each clinical question, bias risk of each evidence has been estimated. Taken together with the estimation of body of evidence, the recommendation for the each clinical question will be determined. In addition to clinical questions, review paper regarding the clinical issues of hyperuricemia and gout will be prepared. Thus, this guideline is expected to cover the decision making regarding the important clinical issues on hyperuricemia and gout.